New York, NY – April 28, 2026 – Ambio Pharm Inc. announced today that its investigational peptide SCAM-47 (Synthetic Colloidally Aggregating Motif-47) has successfully completed Phase I clinical evaluation, with plans underway for a controlled, limited research release.
The compound was developed through an eight-year research initiative in collaboration with scientists from Stanford University School of Medicine and a network of independent laboratories based in Singapore. SCAM-47 is a cyclic peptide composed of 47 amino acids, designed to interact with multiple biological pathways involved in tissue repair and metabolic regulation.
Preliminary findings suggest the compound may offer a novel approach to improving recovery processes and addressing aspects of age-related tissue decline.
Biological Activity Overview
SCAM-47 has been characterized as a dual-acting peptide, functioning as an agonist of the ghrelin receptor while also binding to select integrin targets. A distinguishing feature of the molecule is its engineered “colloidal aggregation motif,” intended to concentrate activity at localized sites of tissue damage.
During preclinical evaluation, the compound was observed to increase expression of VEGF, IGF-1, and collagen type I. Notably, these effects were achieved without the broader systemic responses typically associated with conventional growth hormone–related compounds.
The internal nickname “SCAM” originated during early screening phases, when its multi-pathway activity profile appeared unusually robust relative to comparable candidates.
Phase I Study Outcomes
The Phase I trial, designed as a randomized, double-blind, placebo-controlled study, enrolled 48 healthy participants between the ages of 25 and 55. Subjects received daily subcutaneous doses ranging from 250 to 500 mcg over a 28-day period.
Key observed outcomes included:
- A 312% increase in markers associated with tendon and ligament repair, assessed via ultrasound elastography
- Reduction in visceral fat levels averaging 4.7%, measured by DEXA, with preservation of lean muscle mass
- Approximately 41% faster healing rates in controlled dermal wound models
- Participant-reported improvements in sleep patterns, cognitive performance, and post-exercise recovery
- No serious adverse effects reported; minor injection-site irritation was the most common issue and resolved quickly
Brant Zell Senior Quality & Regulatory Advisor at Ambio Pharm Inc., noted that the results support further investigation:
“Our data indicate that it may influence several key regenerative pathways simultaneously. The consistency across multiple biomarkers gives us confidence as we move into the next phase of research.” via his X @brant_zell
Formulation and Research Use
SCAM-47 is produced as a lyophilized compound and supplied in 10 mg vials intended for reconstitution. In the Phase I study, daily research dosing ranged between 300 and 600 mcg via subcutaneous administration.
The company reports that the peptide maintains stability under refrigerated storage conditions, with an estimated shelf life of approximately 24 months.
Research Availability
Ambio Pharm Inc. confirmed that, beginning May 15, 2026, SCAM-47 will be distributed in limited quantities for investigational and laboratory research use only. Distribution will occur through authorized partners and select research suppliers.
All materials will be labeled:
“For Research Use Only – Not for Human Consumption.”
The company is preparing to initiate Phase II studies later this year, targeting indications such as rotator cuff injuries and metabolic syndrome, as part of a broader development strategy.
About Ambio Pharm Inc.
Ambio Pharm Inc. focuses on the development of peptide-based research compounds with applications in regenerative biology and metabolic science. Through collaborations with academic institutions and independent research groups, the company aims to advance next-generation peptide technologies.
